Form 483

Specialty Formulations & Manufacturing, LLC Form 483, 2019-02-20

FDA issued a Form 483 to Specialty Formulations & Manufacturing, LLC on 2019-02-20 with 8 public-safe observations.

483· Form 483 issuedHuman Drugs8 observations

Specialty Formulations & Manufacturing, LLC · Phoenix, United States · Issued February 20, 2019

Overview

  • 8 public-safe observations are available for this inspection.
  • 7 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

20 Feb 2019
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Christopher M Jenner

20 Feb 2019
21 CFR 211.165(a)

Testing and release for distribution

Cited by Christopher M Jenner

20 Feb 2019
21 CFR 211.166(a)

Lack of written stability program

Cited by Christopher M Jenner

20 Feb 2019
21 CFR 211.188(b)

Batch production and Batch Control Record Requirements

Cited by Christopher M Jenner

20 Feb 2019
21 CFR 211.22(a)

Lack of quality control unit

Cited by Christopher M Jenner

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(a)Cited across public-safe Form 483 observations2x
21 CFR 211.165(a)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)Cited across public-safe Form 483 observations1x
21 CFR 211.188(b)Cited across public-safe Form 483 observations1x
21 CFR 211.22(a)Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(2)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 8 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere